October 13, 2025

Women With Gynecologic Cancers More Likely to Leave The Workforce

Older age, lower income, and depression increased resignation risk across all cancer cohorts.

Conexiant

September 17, 2021

Expert Point of View: Thomas Herzog, MD

Dr. Thomas Herzog discusses the fuzuloparib abstract, its implications, and safety profile, providing valuable insights into PARP inhibitors in ovarian cancer.

The ASCO Post

June 27, 2025

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

The phase III NRG Oncology GOG-0263 trial—results of which were presented during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer—examined whether...

The ASCO Post

March 09, 2021

Baptist Health’s Miami Cancer Institute Brings World-Class Cancer Care to Broward

Many of the innovative cancer-fighting therapies that have placed Baptist Health’s Miami Cancer Institute among Florida’s top cancer programs since its founding just four years ago are now available to cancer patients in Broward County, according to Michael J. Zinner, M.D., the institute’s founding CEO and executive medical director.

Baptist Health South Florida

March 29, 2023

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse eve...

The ASCO Post

May 11, 2023

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting

Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.

Dana-Farber

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

Exciting updates from the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer highlight significant improvements in advanced or recurrent endometrial cancer treatment, particularly for patients with specific genetic profiles. Leading expert Dr. Gini F. Fleming shares insights on new approaches and ongoing trials.

The ASCO Post

May 11, 2023

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

A new Wee1 kinase inhibitor, adavosertib, showed promising antitumor activity but also raised safety concerns in patients with recurrent or persistent uterine serous carcinoma. The findings were presented by Joyce F. Liu, MD, MPH at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer.

The ASCO Post